CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Bioithas is creating ScleroTest, a diagnostic tool that uses gut microbiota to predict treatment responses in multiple sclerosis patients. This non-invasive test aims to improve personalized medicine by enabling timely and accurate therapy choices, enhancing patient outcomes and reducing healthcare costs.
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system currently affecting about 2.5 million people worldwide (mainly young adults, three times more women than men).
There is no cure and therapies do not properly work in all patients.
Personalized medicine is needed but we lack predictive biomarkers for treatment response to secure prompt and early treatment and the best clinical outcomes for each patient.
Thus, MS represents a major public health i…
BIOITHAS SL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
